Hamsell Alvarez serves as the Director and Senior Principal Research Scientist at AbbVie, where he leverages over 13 years of extensive experience in T/NK immunology and protein engineering to drive innovative drug discovery initiatives. In his current role, Hamsell is at the forefront of developing...
Hamsell Alvarez serves as the Director and Senior Principal Research Scientist at AbbVie, where he leverages over 13 years of extensive experience in T/NK immunology and protein engineering to drive innovative drug discovery initiatives. In his current role, Hamsell is at the forefront of developing immuno-cytokines, cytokine receptor antibodies, and multispecific biologics, with a particular focus on advancing immuno-oncology therapies. His expertise encompasses a broad spectrum of methodologies, including target validation, in vitro and in vivo pharmacology, and structural biology, which are critical for the successful development of biologics.
Hamsell's leadership in key projects has led to significant advancements in the evaluation of antagonist and agonist antibodies, bispecifics, and immuno-cytokines. His proficiency in techniques such as ELISA, Western blotting, and X-ray crystallography enables him to conduct rigorous assessments of protein interactions and therapeutic efficacy. Additionally, his experience in pharmacokinetics (PK) and absorption, distribution, metabolism, and excretion (ADME) studies ensures that the biologics developed under his guidance are not only effective but also safe for clinical application.
A collaborative leader, Hamsell excels in project management, fostering cross-functional teamwork to streamline the drug discovery process. His commitment to innovation and excellence in the field of immuno-oncology positions him as a key contributor to AbbVie’s mission of delivering transformative therapies to patients. With a keen eye for emerging biomarkers and a solid foundation in proteomics, Hamsell Alvarez continues to push the boundaries of what is possible in the realm of biologic therapies, making a lasting impact on the future of cancer treatment.
